2023 Was a tricky 12 months to the biopharma industry, with various businesses downsizing and restructuring their workforces to stay afloat. You can find indications of recovery, as mergers and acquisitions picked up over the pharmaceutical and everyday living sciences industry in the latter Component of 2023 and have continued https://sites.google.com/view/bio-sites/blog